BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27987320)

  • 1. Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer.
    Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Shaaban AM; Humphries MP; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
    J Cell Physiol; 2017 Aug; 232(8):2246-2252. PubMed ID: 27987320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
    Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
    Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAZ expression as a prognostic indicator in colorectal cancer.
    Yuen HF; McCrudden CM; Huang YH; Tham JM; Zhang X; Zeng Q; Zhang SD; Hong W
    PLoS One; 2013; 8(1):e54211. PubMed ID: 23372686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Vici P; Ercolani C; Di Benedetto A; Pizzuti L; Di Lauro L; Sperati F; Terrenato I; Gamucci T; Natoli C; Di Filippo F; Botti C; Barba M; Mottolese M; De Maria R; Maugeri-Saccà M
    J Exp Clin Cancer Res; 2016 Apr; 35():62. PubMed ID: 27039292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
    Melucci E; Casini B; Ronchetti L; Pizzuti L; Sperati F; Pallocca M; De Nicola F; Goeman F; Gallo E; Amoreo CA; Sergi D; Terrenato I; Vici P; Di Lauro L; Diodoro MG; Pescarmona E; Barba M; Mazzotta M; Mottolese M; Fanciulli M; Ciliberto G; De Maria R; Buglioni S; Maugeri-Saccà M
    J Transl Med; 2018 Feb; 16(1):22. PubMed ID: 29402328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YES-associated protein 1 promotes adenocarcinoma growth and metastasis through activation of the receptor tyrosine kinase Axl.
    Cui ZL; Han FF; Peng XH; Chen X; Luan CY; Han RC; Xu WG; Guo XJ
    Int J Immunopathol Pharmacol; 2012; 25(4):989-1001. PubMed ID: 23298489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.
    Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Shaaban AM; Sundara-Rajan S; Humphries MP; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
    Sci Rep; 2016 Oct; 6():35121. PubMed ID: 27713571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma.
    Li J; Shi C; Zhou R; Han Y; Xu S; Ma H; Zhang Z
    Cancer Sci; 2020 Sep; 111(9):3222-3235. PubMed ID: 32589311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation.
    Li H; Wang S; Wang G; Zhang Z; Wu X; Zhang T; Fu B; Chen G
    Dig Surg; 2014; 31(6):468-78. PubMed ID: 25632982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues.
    Cao L; Sun PL; Yao M; Jia M; Gao H
    Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Yes-associated protein (YAP) in breast phyllodes tumor.
    Kim SK; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2014; 7(9):5997-6005. PubMed ID: 25337244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAZ and YAP are frequently activated oncoproteins in sarcomas.
    Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
    Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder.
    Liu JY; Li YH; Lin HX; Liao YJ; Mai SJ; Liu ZW; Zhang ZL; Jiang LJ; Zhang JX; Kung HF; Zeng YX; Zhou FJ; Xie D
    BMC Cancer; 2013 Jul; 13():349. PubMed ID: 23870412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse.
    Corvaisier M; Bauzone M; Corfiotti F; Renaud F; El Amrani M; Monté D; Truant S; Leteurtre E; Formstecher P; Van Seuningen I; Gespach C; Huet G
    Oncotarget; 2016 Aug; 7(35):56699-56712. PubMed ID: 27527859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
    Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
    Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma.
    Chen PX; Li QY; Yang Z
    Ann Diagn Pathol; 2013 Oct; 17(5):425-9. PubMed ID: 23707658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.
    Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S
    Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation Between Immunohistochemical Expression of Hippo Pathway Effectors and Chronic Hepatitis Induced Fibrosis in Egyptian Patients.
    Abdallah RA; Shaban MI; Taie DM; Asaad NY; Badr A
    Turk Patoloji Derg; 2020; 36(1):48-63. PubMed ID: 31282549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk between Hippo and TGFβ: Subcellular Localization of YAP/TAZ/Smad Complexes.
    Grannas K; Arngården L; Lönn P; Mazurkiewicz M; Blokzijl A; Zieba A; Söderberg O
    J Mol Biol; 2015 Oct; 427(21):3407-15. PubMed ID: 25937570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.